INCOGNITO-SOFTWARE
Incognito Software Systems Inc. , a leading global provider of broadband service orchestration software solutions for digital service providers, announces that Optima Italia S.p.A. has gone live with Incognito’s Digital Experience (DX) Solution to streamline and improve the customer experience. With Incognito, Optima can centralize and streamline the management of all devices in its network to deliver an uninterrupted, high-quality customer experience using a carrier-grade solution that can scale with their network and service growth.
As a leading Italian digital company service provider, Optima offers an integrated collection of services, including electricity, gas, mobile, and Internet for business and residential markets. To support a significant and growing customer base across major centers, Optima required a solution to scale operations by replacing time- and labor-intensive manual processes with an industry awarded platform. Underpinned by Incognito’s fully featured Broadband Forum-compliant Auto Configuration Server (ACS) , the Digital Experience smart platform automates the resolution of technical issues that impact service quality.
Optima selected Incognito to support them in their automation efforts based on Incognito’s expertise enhancing subscriber experience, reducing operational costs, and supporting the delivery of innovative services into the connected home. “It was quickly apparent that Incognito could offer a great platform implementation, with system go-live in a matter of weeks,” said Paolo Primiani, Network & Voice engineer at Optima Italia.
“We are very proud to be working with Optima Italia as a technology partner for their rollout of high-speed fiber broadband services to customers across its service areas,” said Ricardo Gonzalez, VP of Sales at Incognito. “Optima is one of the leading broadband providers in Italy, respected for their dedication to customer experience. Our mission is to provide telecom operators with tools that help them increase efficiency while reducing costs, and we look forward to contributing to Optima’s success.”
The Digital Experience Solution (DX) is an industry awarded platform, used around the world by premier broadband service providers to manage and orchestrate internet of things (IoT) and customer premise equipment (CPE) with Broadband Forum’s TR-069, User Services Platform (USP / TR-369) , and other management protocols. To learn more about Digital Experience Solution and Incognito’s suite of orchestration solutions, visit www.incognito.com .
About Incognito
Incognito Software Systems Inc. provides service orchestration software and services that help digital service providers manage the next-generation broadband experience. Over 200 customers worldwide, including Claro, Cox, Digicel, Globe, and Orange, leverage Incognito solutions to fast-track the introduction of innovative broadband services over fiber, cable, and fixed wireless technologies, while delivering a great customer experience. The company is a division of the Lumine Group , a portfolio of Constellation Software Inc. , the largest independent software company in Canada. Visit www.incognito.com or follow us on LinkedIn and Twitter .
About Optima Italia
Optima Italia S.p.A., is a leading Italian digital company for the integrated provision of energy (electricity and gas) and telecommunications (internet, telephone, and mobile) services for the business and consumer markets. Optima was founded in 1999 by entrepreneurs Danilo Caruso and Alessio Matrone with the objective of creating a service company to simplify life for families and businesses. Visit www.optimaitalia.com , or follow on LinkedIn .
View source version on businesswire.com: https://www.businesswire.com/news/home/20220314005117/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Andersen Consulting tilføjer samarbejdsfirmaet Codezilla7.12.2025 21:19:00 CET | Pressemeddelelse
Andersen Consulting styrker sine kompetencer inden for digital transformation gennem en samarbejdsaftale med Codezilla, et firma med hovedsæde i Rumænien, der udvikler specialtilpasset software. Codezilla specialiserer sig i at udvikle skræddersyede softwareprodukter, der løser forretningsmæssige udfordringer gennem en tværfaglig tilgang, som kombinerer softwareudvikling med dybdegående marketingekspertise. Med over 30 år på markedet fungerer firmaet som implementerings- og digital konsulentressource for reklamebureauer, samtidig med at de arbejder med en bred kundebase, herunder virksomheder inden for sundhedssektoren og medicinsk udstyr. Codezillas interne teams strækker sig over teknik, design og strategi og leverer omnichannel-løsninger til både regionale og globale kunder. "Vi tror på, at fantastisk software er resultatet af solid ingeniørkunst og disciplineret eksekvering," udtaler Sebastian Doroftei, administrerende direktør for Codezilla. "Vores samarbejde med Andersen Consulti
Hemato-Oncology Trials: AOP Health Presents New Results at Top Congress ASH7.12.2025 17:00:00 CET | Press release
AOP Health continues to advance its clinical research program in myeloproliferative neoplasms, a special group of rare blood cancers. The company, specialized in rare diseases, presented the results of two scientific investigations at the 67th American Society of Hematology Association (ASH) Annual Meeting 2025 held in Orlando, FL, USA. The results provide new insights in treatment strategies. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251207587915/en/ Dr. Martin Steinhart, CEO AOP Health; Photo credit: AOP Health/Studio Koekart ROP-ET and BESREMI PASS One of the clinical studies, ROP-ET, examined the use of ropeginterferon alfa-2b in people with essential thrombocythemia (ET), a disease in which the body produces too many platelets. The trial, a prospective, multicenter, single-arm phase III study, investigated the safety and efficacy of ropeginterferon alfa-2b in ET patients unable to receive available cytoreductive th
CoMotion GLOBAL 2025 Launches in Riyadh: Global Mobility Leaders Unite in Saudi Capital to Chart Urban Future7.12.2025 13:00:00 CET | Press release
Summit debuts Mayors in Motion initiative and CoMotion Urban Visionary Distinction as Riyadh showcases its rise as global mobility testbed Riyadh is rapidly becoming one of the world's most ambitious urban mobility laboratories, where next-generation technologies move from blueprint to real-world deployment on city streets at unprecedented scale. CoMotion GLOBAL 2025, the world's most influential gathering of urban mobility leaders, opens today in Riyadh for a three-day summit bringing together innovators from Africa, Asia, Europe, the Americas, and the Middle East. Running December 7-9, the event will explore how electrification, autonomy, AI-enabled transport, and giga-project urbanism are reshaping cities worldwide. The summit will spotlight everything from high-performance EVs and breakthrough autonomous fleets to emerging-market transport solutions and new mobility models, demonstrating how the Kingdom is opening new pathways for global mobility leadership. Strategic Partnerships
Deciphera Announces Oral Presentation of Positive Topline Results from Phase 2a Study of Sapablursen in Polycythemia Vera at the 67th American Society of Hematology (ASH) Annual Meeting6.12.2025 15:30:00 CET | Press release
Results from Phase 2a IMPRSSION study demonstrate sapablursen significantly reduced phlebotomy rate, controlled hematocrit and increased serum hepcidin Sapablursen was generally safe and well tolerated Results support further development of sapablursen in a Phase 3 study Deciphera Pharmaceuticals, a member of Ono Pharmaceutical Co., Ltd. (Headquarters: Osaka, Japan; President and COO: Toichi Takino; “Ono”), today announced the oral presentation of positive results from the Phase 2a IMPRSSION study of sapablursen in patients with polycythemia vera (PV) at the 67th American Society of Hematology (ASH) Annual Meeting, taking place December 6-9, 2025, in Orlando, FL. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251206361611/en/ The results were presented by Ionis Pharmaceuticals, who discovered and developed sapablursen and conducted the IMPRSSION study. In March 2025, Ionis and Ono entered into a license agreement in which On
Protagonist and Takeda Present Longer-Term Data at ASH 2025 Showing Rusfertide Delivers Durable Response and Hematocrit Control in Polycythemia Vera6.12.2025 15:30:00 CET | Press release
52-Week Results from the Phase 3 VERIFY Study of Rusfertide Demonstrated Sustained Hematocrit Control and Response, Defined by Absence of Phlebotomy Eligibility, with No New Safety SignalsThese Data Build on Positive 32-Week Primary Analysis from VERIFY, Which Met its Primary Efficacy Endpoint and All Four Key Secondary EndpointsPatients Crossing Over from Placebo to Rusfertide at 32 Weeks Achieved a Similar Response Rate to Those Initially Randomized to Rusfertide, with 77.9% Achieving Absence of Phlebotomy Eligibility Between Weeks 40-52Four-Year Results from the Combined REVIVE and Long-Term Extension THRIVE Study Demonstrated a 13-Fold Reduction in Annual Rate of Phlebotomies from Baseline Protagonist Therapeutics, Inc. (“Protagonist”) (NASDAQ:PTGX) and Takeda (TSE:4502/NYSE:TAK) announce that new 52-week results from the pivotal Phase 3 VERIFY study evaluating rusfertide in patients with polycythemia vera (PV) will be presented in an oral presentation at the 67th American Society
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom